First-order elimination and what a half-life means
In a first-order model, a constant fraction of what is present is eliminated per unit time. That gives exponential decay, and the half-life is the time for the amount to fall by half regardless of where it started.
The practical consequence is the five half-lives rule. After one half-life 50 percent remains, after two 25, after three 12.5, and after five about three percent, which is close enough to gone for most purposes.
Accumulation, and why the interval matters more than the amount
If a second amount arrives before the first has cleared, the two overlap. Repeat that and the concentration climbs to a plateau where the amount eliminated per interval equals the amount arriving.
The plateau depends on the ratio of interval to half-life, not on the size of each amount. An interval equal to the half-life gives a twofold accumulation. An interval of half the half-life gives about 3.4-fold. An interval of three half-lives gives about 1.14-fold, which is practically none.
- •Interval equal to the half-life: 2-fold accumulation
- •Interval of half the half-life: about 3.4-fold
- •Interval of two half-lives: about 1.33-fold
- •Interval of three half-lives: about 1.14-fold
Time to steady state is set by half-life alone
Reaching the plateau takes about five half-lives, and that figure does not depend on the interval or the amount. Changing the amount changes the height of the plateau; it does not change how long it takes to get there.
This is why a peptide with a week-long half-life takes over a month to plateau however it is administered.
What a one-compartment model leaves out
It assumes instant appearance, which is wrong for anything absorbed rather than injected intravenously. Real curves rise to a peak over a period set by absorption and then decline.
It assumes the body is one well-mixed compartment. Real distribution into tissues produces a two-phase curve, a fast distribution phase and a slower elimination phase, and a single reported half-life usually refers to the terminal phase only.
Why the trough figure was wrong here before
The plotter used to look for the trough by testing whether a sampled time point coincided exactly with a dosing time. On a floating-point sample grid that is almost never true, so the running minimum stayed at its initial value and the tool reported a trough of zero for most inputs.
Troughs are now evaluated at the dosing times directly, and the steady-state peak and trough are computed in closed form so they do not depend on how long a window happened to be plotted.
How the concentration curve is calculated
Superposition of exponentially decaying inputs, sampled densely enough to draw, with the steady-state values taken from the closed-form expressions rather than read off the sampled curve.
k = ln(2) / half-life C(t) = SUM over past doses of D x e^(-k(t - t_dose)) accumulation = 1 / (1 - e^(-k x interval)) steady peak = D x accumulation steady trough = D x accumulation x e^(-k x interval) time to plateau = about 5 half-lives
- Convert half-life to a rate constant. The natural logarithm of two divided by the half-life. This is the fraction eliminated per unit time in the exponential.
- Superpose the inputs. Each amount decays independently from the moment it arrives, and the concentration at any time is the sum of all of them. Linear kinetics is what makes this valid.
- Sample either side of each input. The curve is sampled just before and just after every dosing time, so the plot shows the vertical step a bolus produces rather than a diagonal ramp into it.
- Read troughs at the dosing times. Evaluated directly at each dose time rather than searched for on the sample grid, which is what the previous implementation attempted and almost always failed to find.
- Compute steady state in closed form. The accumulation ratio and the steady peak and trough come from the analytic expressions, so they are independent of how long a window is plotted.
What this method cannot tell you
- •One compartment with instant input. Real absorption produces a rise to a peak that this model does not show.
- •Single-phase elimination. Most real curves have a distribution phase and an elimination phase with different slopes.
- •Linear kinetics. At saturating concentrations elimination becomes concentration-independent and the model breaks.
- •The concentration axis is in arbitrary units of one amount. It is a shape, not a prediction of any measurable level.
Half-life plotter: frequently asked questions
The time for the amount present to fall by half. In first-order elimination it is constant, independent of the starting amount.
After five half-lives about three percent remains, which is the origin of the rule that five half-lives is effectively complete clearance.
The rate constant k is the natural logarithm of two divided by the half-life, which is about 0.693 over the half-life.
It is the fraction eliminated per unit time and it is what appears in the exponential.
The buildup that happens when a second amount arrives before the first has cleared. The concentration climbs to a plateau where elimination per interval matches input per interval.
The ratio of the interval to the half-life, and nothing else. The size of each amount sets the height of the plateau, not the accumulation factor.
- •Interval equal to the half-life: 2-fold
- •Interval of two half-lives: about 1.33-fold
- •Interval of three half-lives: about 1.14-fold
About five half-lives, and that figure does not depend on the interval or the amount.
Changing the amount changes the plateau height, not the time taken to reach it.
The highest point, immediately after an input, and the lowest, immediately before the next one.
At steady state the difference between them is exactly one input's worth, which is a useful check on any accumulation calculation.
Because the tool searched for the trough by testing whether a sampled time coincided exactly with a dosing time, which on a floating-point grid is almost never true.
Troughs are now evaluated at the dosing times directly, and the steady-state values come from closed-form expressions.
The simplest pharmacokinetic model, treating the body as a single well-mixed volume from which the substance is eliminated at a rate proportional to its concentration.
It captures the shape of accumulation and clearance and omits absorption and tissue distribution.
Because distribution into tissues happens faster than elimination, producing an initial steep fall followed by a shallower one.
A single quoted half-life usually refers to the terminal elimination phase. The distribution half-life is separate and shorter.
No. It assumes each amount appears instantly, which is true for an intravenous bolus and not for anything absorbed.
Real curves rise to a peak over a period set by the absorption rate. The accumulation behaviour is still approximately right.
Because clearance depends on size, charge, protease susceptibility and protein binding, and peptides differ enormously in all four.
Small unmodified peptides are cleared in minutes. Lipidated peptides that bind albumin last days, because binding shields them from filtration and from proteases.
Chiefly by increasing effective size or by promoting binding to a long-lived carrier.
- •Pegylation increases hydrodynamic radius and slows renal filtration
- •Lipidation promotes albumin binding, which shields the peptide
- •D-amino acids and cyclisation resist protease cleavage
Arbitrary units of one input. The plot shows the shape of accumulation and clearance, not a predicted measurable concentration.
Converting to real units needs a volume of distribution and a bioavailability figure, neither of which the model has.
The steady-state peak divided by the peak after a single input. It equals one over one minus e to the minus k times the interval.
A ratio of two means the steady-state peak is twice the first peak.
No. It is an educational illustration of first-order kinetics and it omits absorption, distribution, protein binding and individual variation.
Because the approach to the plateau is itself exponential with the same rate constant. After five half-lives the gap to the plateau has closed to about three percent.
Related Products
Related Research News
MOTS-c Half-Life: What Studies Show and What Remains Unknown
This reference clarifies what primary studies have established about MOTS-c half-life and stability, and identifies the pharmacokinetic questions that remain unanswered in humans.
BPC 157 Half-Life: Published Evidence and Research Status
This article reviews published evidence on BPC 157's stability and distribution, clarifying that no formal half-life determination exists. It distinguishes documented findings from vendor claims.
BPC-157 for Dogs: Benefits, Research and the Two Canine Studies
Go through the BPC-157 literature looking for studies that involved dogs and you find two: one toxicology, one pharmacokinetics. Neither asks whether it heals anything. What the canine evidence actually contains, why the published dosing charts disagree by more than 20-fold, and what the 2026 reviews concluded.



